Chengdu Origiant Pharmaceutical

Origiant Pharmaceutical is a clinical-stage biotechnology company based in Chengdu, China, focused on the discovery and development of innovative small molecule immunotherapies for cancer and autoimmune disorders. The company specializes in modulating the tumor microenvironment to overcome immune suppression, with a particular emphasis on the adenosine pathway and kinase signaling. Its lead clinical candidate, OGT2150, is a highly selective Adenosine A2a receptor antagonist designed to enhance T-cell activity against solid tumors. Origiant leverages its proprietary drug discovery platform to develop a pipeline of high-potency candidates, including HPK1 inhibitors and STING agonists, aimed at converting cold tumors into hot tumors. The leadership team consists of industry veterans with extensive experience in global drug development and medicinal chemistry.